---
title: "ARVN: First FDA-approved PROTAC and out-licensing drove record Q2 revenue and net income"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294814734.md"
description: "Achieved first FDA approval and out-licensing of a PROTAC degrader, driving a surge in revenue and net income for Q2 2026. Multiple clinical programs advanced, with key data readouts and a strong cash position supporting operations into 2028.Original document: Arvinas, Inc. [ARVN] SEC 8-K Current Report — Aug. 4 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-04T11:21:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294814734.md)
  - [en](https://longbridge.com/en/news/294814734.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294814734.md)
---

# ARVN: First FDA-approved PROTAC and out-licensing drove record Q2 revenue and net income

Achieved first FDA approval and out-licensing of a PROTAC degrader, driving a surge in revenue and net income for Q2 2026. Multiple clinical programs advanced, with key data readouts and a strong cash position supporting operations into 2028.

Original document: Arvinas, Inc. \[ARVN\] SEC 8-K Current Report — Aug. 4 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ARVN.US](https://longbridge.com/en/quote/ARVN.US.md)

## Related News & Research

- [Arvinas posts corporate presentation highlighting PROTAC degrader pipeline in oncology and neurology](https://longbridge.com/en/news/295231676.md)
- [The protein-shredding revolution: Why Arvinas gave away the keys to its historic FDA approval](https://longbridge.com/en/news/291659953.md)
- [10:01 ETNetwork-attached Storage (NAS) Market worth $97.44 billion by 2032 - Exclusive Report by MarketsandMarkets™](https://longbridge.com/en/news/296240408.md)
- [Impact Therapeutics names IMP2794 KAT6A PROTAC degrader as preclinical candidate](https://longbridge.com/en/news/295640139.md)
- [Arvinas' (ARVN) "Equal Weight" Rating Reaffirmed at Wells Fargo & Company](https://longbridge.com/en/news/294856225.md)